New Roche PD-L1 Tecentriq shines in study of untreated bladder cancer patients

Roche

CHICAGO--Highly anticipated Roche immunotherapy Tecentriq hit the scene just last month with an FDA approval to treat advanced bladder cancer in patients who’ve failed on platinum-based chemotherapy. But the company already has data in hand that could help snag a first-line go-ahead, too.

In a Phase II study of patients ineligible for standard cisplatin chemo, 24% saw their tumors shrink--and that number went as high as 28% in patients with higher levels of PD-L1 expression, Dan Chen, head of cancer immunotherapy development for Roche’s Genentech unit, told FiercePharma.

Three-fourths of those who responded did not see their cancers worsen after an average follow-up of 14.4 months. And 7% of study participants achieved a complete response, showing no sign of disease. The data were presented Sunday at the American Society of Clinical Oncology’s annual meeting here.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

As Chen pointed out, the response rate seen in the study was even higher than the one Tecentriq posted in the second-line setting, which came in at 16%. “The concept of immunotherapy working better as you get into earlier lines of therapy is one that we very much want to test. We think it’s possible, and we think this data supports the idea,” he said, noting that Roche hopes to eventually extend even into adjuvant therapy with Tecentriq.

Entering the first-line setting, which boasts a wider pool of patients that generally stay on therapy longer, would also expand sales of the young Roche drug, which is the third checkpoint inhibitor on the market behind Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo. Its rivals have been racing to rack up approvals in melanoma and lung cancer, and Opdivo recently nailed down a go-ahead in kidney cancer, too.

Roche certainly wouldn’t mind the sales boost. It’s counting on Tecentriq to make hefty top-line contributions--both on its own as a monotherapy and as part of combinations--that’ll help fill the gap as its older cancer superstars come under increased competition. Earlier at ASCO, investigators presented research showing that a Mylan copy of breast cancer star Herceptin had matched the Roche original in terms of efficacy and safety in a Phase III study.

- read the release 

Related Articles:
Roche's Tecentriq bursts onto immuno-oncology scene, with Merck and BMS in its sights​
Roche's atezo gets FDA fast track, BMS, Merck showdown coming
Roche looks ahead to immuno-oncology, MS to back up big-selling cancer meds
Roche's atezo lines up PD-L1 data for forthcoming battle with Keytruda, Opdivo
Roche hustles to FDA with PhII PD-L1 cancer success for 'breakthrough' star atezo
Looking to build Darzalex a bigger market, J&J teams up with Roche for atezo combo trials

Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.